Summary The effect of clodronate on bone mineral density (BMD) was studied in 121 post-menopausal breast cancer women without skeletal metastases. In addition, two antioestrogens, tamoxifen and toremifene, were compared in their action on bone mineral density. Patients were randomized to have an adjuvant antioestrogen treatment either 20 mg of tamoxifen or 60 mg of toremifene daily for 3 years. In addition all patients were randomized to have 1600 mg of oral clodronate daily or to act as control subjects. BMD of the lumbar spine and femoral neck were measured by dual-energy radiographic absorptiometry before therapy and at 1 and 2 years. At 2 years, clodronate with antioestrogens markedly increased BMD in the lumbar spine and femoral neck by 2.9% and 3.7% (P = 0.001 and 0.006 respectively). There were no significant changes in BMD in the patients given antioestrogens only. No significant differences were found between tamoxifen and toremifene on bone mineral density. Clodronate with antioestrogens significantly increased bone mass in the lumbar spine and femoral neck. Both antioestrogens, tamoxifen and toremifene, similarly prevented bone loss in the lumbar spine and femoral neck.
Adjuvant antioestrogen treatment with tamoxifen significantly improves the survival of post-menopausal women with primary breast cancer (EBCTCG, 1992) . Tamoxifen has oestrogen agonistic effects on bone and therefore prevents bone loss in postmenopausal women (Love et al, 1992 ; Ward et al, 1993 ; Kristensen et al, 1994; Powles et al, 1996) . Tamoxifen has been shown to prevent bone loss predominantly in the lumbar spine (Love et al, 1992; Kristensen et al, 1994 ), but in two randomized studies this was also true for the upper femur (Ward et al, 1993; Powles et al, 1996) .
Toremifene is a close analogue to tamoxifen with demonstrated efficacy in advanced breast cancer (Valavaara et al, 1988) . Compared with tamoxifen, toremifene is more oestrogen antagonistic than agonistic in rat (Di Salle et al, 1990) . At present, no data are available on the effect of toremifene on bone.
Since bisphosphonates prevent post-menopausal bone loss (Chesnut 1984; Reginster et al, 1989; Storm et al, 1990; Watts et al, 1990; Giannini et al, 1993; Harris et al, 1993; Reid et al, 1994; Filipponi et al, 1995; Liberman et al, 1995) and in advanced breast cancer reduced the development of new bone metastases (Elomaa et al, 1983; Martoni et al, 1991; Paterson et al, 1993; Van Holten Verzantvoort et al, 1993) , they are attractive candidates for the treatment of patients with early breast cancer. We performed a prospective, open, randomized study to determine the effect of oral clodronate in post-menopausal women with primary breast cancer treated with adjuvant antioestrogens,
MATERIALS AND METHODS Patients and methods
The study population consisted of 121 early-stage breast cancer patients, with no haematogenic metastases. Eligible for the trial were post-menopausal women with operable breast cancer and histologically proven axillary metastases, TI-3 Nl-2 MO, treated between May 1992 and July 1993 at Helsinki University Hospital, Department of Oncology. Exclusion criteria included the following: (1) age above 75 years; (2) Karnofsky performance index below 70%; (3) bone metastases within 6 months after BMD measurement; (4) other malignancies; (5) peptic ulcer or its symptoms; and (6) creatinine over 150 ,mol 1-1. Post-menopausal status at entry was defined as either no menses for more than 1 year or shorter duration of amenorrhoea with follicle-stimulating hormone (FSH) levels in the post-menopausal range.
All patients underwent surgery with axillary clearance and total mastectomy or breast-conserving resection. All patients also had post-operative radiotherapy with megavoltage irradiation (50 Gy in 25 fractions) to regional lymph nodes and operative scar or remaining breast after breast-conserving resection, simultaneously with adjuvant therapy. Patients were randomly allocated to receive adjuvant antioestrogen therapy: 20 mg of tamoxifen per day or 60 mg of toremifene daily for 3 years. In addition, all patients were randomized to receive or not to receive 1600 mg of oral clodronate (Bonefos, Leiras) daily for 3 years.
Informed consent was obtained from all participants. The study was approved by the local ethics committee at the Department of Oncology. Helsinki University Hospital. Staging investigations for breast cancer included clinical investigation, liver ultrasound, chest radiograph and bone scintigraphy. Basic laboratory tests before randomization included a complete blood count and sedimentation rate, liver enzymes (transaminase, alkaline phosphatase and 5-nucleotidase), serum creatinine, calcium and electrolytes. Patients were interviewed regarding menopausal status, medications and other diseases before randomization and every 12 months. Bone scintigraphy and measurements of serum FSH luteinizing hormone (LH) and oestradiol were performed before treatment and every 12 months thereafter. Plasma concentrations of FSH and LH were measured by immunofluorometric assays (IFMA; Wallac, Turku, Finland) and plasma oestradiol levels were measured by a radioimmunoassay (RIA; Farmos, Oulunsalo, Finland). Clinical investigation and basic laboratory safety tests were repeated every 4 months with a radiological examination if necessary.
Bone densitometry
Bone mineral density (BMD, g cm-2) was measured by dual-energy radiographic absorptiometry (DXA) using a Hologic QDR-1000 Thus, 93 patients were eligible for analyses. From the 2 years' analyses, nine additional patients were excluded: eight because of breast cancer recurrence and one patients because of discontinuation of follow-up. Four patients interrupted clodronate treatment: three patients because of side-effects and one patient because of refusal to continue therapy. One patient had a dose reduction because of gastric pain. Five patients interrupted antioestrogen therapy after a median of 10 months: four because of menopausal symptoms and one because of increased serum transaminase levels. All these patients are included in the analyses.
Oral clodronate treatment was well tolerated. Three patients (3%) interrupted clodronate therapy and one patient reduced the dose because of gastric pain. There were no significant differences in adverse events between the study groups. During the first year of therapy, seven patients (8%) reported mild nausea and vomiting, and three patients (3%) had diarrhoea with no differences between the study groups. During the second year four (4%) patients complained about of mild nausea and vomiting, and one patient had diarrhoea. Renal toxicity was not seen in either group.
Hormonal changes
Antioestrogen therapy decreased FSH and LH levels significantly in post-menopausal patients: median FSH from 54.6 U 1-' (range 3.8-109) to 29.9 U 1-1 (9.0-66.1), median LH from 36.0 U 1-' (2.8-94.5) to 20.0 U 1-' (4.4-62.9) (P < 0.0001 and P < 0.0001 respectively, Wilcoxon), with no significant changes in oestradiol levels. There were no significant differences between the tamoxifen and toremifene groups, or between the clodronate and control groups.
The mean weight gain was 1.4 kg (s.d. 2.8) and 1.4 kg (s.d. 4.5) at 1 and 2 years of the study (P < 0.0001 and P < 0.0001 respectively, Wilcoxon); there were no significant differences between the control and clodronate groups, nor between the tamoxifen and toremifene groups.
Changes in bone mineral density
The baseline values for the BMD of the lumbar spine and the femoral neck were similar in the clodronate and control groups (Table 1 ). In patients receiving clodronate, BMD of the lumbar spine increased significantly by 1.5% and 2.9% at 1 and 2 years respectively (within the clodronate group, P = 0.002, and P = 0.002, Wilcoxon), while in the control group BMD of the lumbar spine was unchanged (between the groups, P = 0.004, ANOVA). BMD of the femoral neck increased by 3.3% and 3.7% in the clodronate group at the first and second years (within the clodronate group, P < 0.0001 and P < 0.0001, Wilcoxon), with no significant changes in the control group (between the groups, P = 0.003, ANOVA) (Figure 1) .
Changes of BMD in the tamoxifen and toremifene groups are shown in Table 2 . The type of endocrine treatment had no significant effect on the BMD of the lumbar spine and femoral neck (at 2 years, P = 0.446 and P = 0.064 respectively).
DISCUSSION
The present study implies that adjuvant antioestrogen treatment with either tamoxifen or toremifene prevents bone loss in postmenopausal women. However, bone mineral density can even be augmented by combining clodronate with the medical treatment of post-menopausal women with breast cancer.
In line with prior investigations, post-menopausal breast cancer patients treated with antioestrogens did not lose bone at the lumbar spine or at the femoral neck (Love et al, 1992; Ward et al, 1993; Kristensen et al, 1994; Powles et al, 1996) . Previous data on tamoxifen were extended by the finding that a novel antioestrogen, toremifene, preserved bone mass as effectively as tamoxifen, although experimental data havo shown it to be less oestrogenic than tamoxifen (Di Salle et al, 1990) . Clodronate provided an additional benefit for post-menopausal breast cancer patients. In fact, the clodronate-induced increase in bone mass was quite similar to that obtained on oestrogen replacement therapy after a natural menopause (Ettinger et al, 1987 (Ettinger et al, , 1992 Stevenson et al, 1990) .
Our results indicate that clodronate combined with antioestrogens augment bone mass in post-menopausal women. A new antioestrogen, toremifene, had an oestrogen-like effect on bone similar to tamoxifen. Since clodronate can also inhibit the development of bone metastases, it appears to be an attractive adjuvant treatment for women with breast cancer.
